Valiant Laboratories Ltd

Desk›Healthcare› Valiant Laboratories Ltd

Valiant Laboratories Ltd

BSE 543998 · NSE VALIANTLAB · ISIN INE0JWS01017 · Group B · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹100.48

-4.99%

BSE close, 28 August 2026

Market cap

₹545.73 cr

5.4 cr shares · Micro cap

Free float

₹136.76 cr

as published

P/E · P/B

41.4× · 2.37×

EPS ₹2.43 · BV ₹42.40

FY25-26 rev / PAT

217.04 / 5.55

₹ cr, as filed

Filings, window

5 selected · 24%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

Against 52-week high	-9.3%
Against 52-week low	+101.0%
Day change	-4.99%
Size band	Micro cap
Index membership	None

Valuation as published by BSE

Earnings per share	₹2.43
Price / earnings	41.35×
Price / book	2.37×
Book value — derived, price ÷ P/B	₹42.40
Return on equity	5.75%
Operating margin	18.19%
Net margin	12.91%

Consistency check

P/B ÷ P/E, which must equal ROE: 5.73%
ROE as published: 5.75%

Results ₹ crore, as filed

Jun-26 · Q

Mar-26 · Q

FY25-26

RevenueNet profit one scale across all three periods, ₹ crore

Period	Revenue ₹cr	Net profit ₹cr	EPS ₹	OPM	NPM
Jun-26 · Q	73.42	9.48	1.75	18.19%	12.91%
Mar-26 · Q	65.30	3.53	0.65	8.07%	5.41%
FY25-26	217.04	5.55	1.02	4.64%	2.56%

Quarter on quarter

Revenue, quarter on quarter: +12.4%
Net profit, quarter on quarter: +168.6%
Operating margin, quarter on quarter: +1,012 bps

Disclosure profile 21 filings in the window

Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.

Tag	Filings
Selected
Acquisition	1
Board Outcome	1
Change in Directorate	1
Credit Rating	1
Results	1
Selected sub-total	5
Procedural
AGM / EGM	4
Newspaper Publication	3
General	2
Annual Report	1
Board Meeting	1
Monitoring Agency	1
Outcome	1
Registered Office	1
Subsidiary Incorporation	1
Trading Window	1
Procedural sub-total	16
Total	21

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

21 filings · 5 selected · busiest 2026-08-10

Filing rhythm · the twelve most recent

2026-08-312026-09-29

SelectedProcedural

Filings

21 in the window · 2 earlier on record

29 September 2026 · 17:54 IST

Trading Window

Closure of Trading Window

Closure of Trading Window for declaration of Financial Results for the quarter and half year ended September 30, 2026.

Insider Trading / SAST / Closure of Trading Window View filing →
29 September 2026 · 17:46 IST

AGM / EGM

Shareholder Meeting / Postal Ballot-Scrutinizer's Report

Scrutinizer's Report and Voting Results of 5th AGM of Valiant Laboratories Limited.

AGM/EGM / AGM View filing →
29 September 2026 · 17:45 IST

AGM / EGM

Shareholder Meeting / Postal Ballot-Scrutinizer's Report

Scrutinizer's Report and Voting Results of 5th AGM of Valiant Laboratories Limited.

AGM/EGM / AGM View filing →
28 September 2026 · 17:52 IST

AGM / EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings of 5th Annual General Meeting of Valiant Laboratories Limited held through VC/OAVM.

AGM/EGM / AGM View filing →
17 September 2026 · 12:17 IST

Outcome

Board Meeting Outcome for Investment In AMPYR Renewable Energy Resources Twelve A Private Limited

Please find enclosed

Others / Outcome without intimation View filing →
17 September 2026 · 12:13 IST

Acquisition

Acquisition

Please find enclosed

Company Update / Acquisition View filing →
4 September 2026 · 12:25 IST

Newspaper Publication

Newspaper Publication

Newspaper Advertisement regarding Completion of Dispatch of Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to the Members of the Company

Company Update / Newspaper Publication View filing →
3 September 2026 · 17:40 IST

Credit Rating

Credit Rating

Credit Rating issued by India Ratings & Research Private Limited

Company Update / Credit Rating View filing →
3 September 2026 · 17:30 IST

General

Letter To Shareholders

Letter to Shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015

Company Update / General View filing →
3 September 2026 · 17:15 IST

AGM / EGM

Notice Of 5Th Annual General Meeting And Annual Report For FY 2025-26

Notice of 5th AGM and Annual Report for FY 2025-26

AGM/EGM / AGM View filing →
3 September 2026 · 17:01 IST

Annual Report

Reg. 34 (1) Annual Report.

Annual Report for FY 2025-26.

Others / Reg. 34 (1) Annual Report View filing →
31 August 2026 · 12:05 IST

Newspaper Publication

Newspaper Publication

Newspaper Advertisement w.r.t. 5th AGM of the Company.

Company Update / Newspaper Publication View filing →
12 August 2026 · 12:13 IST

Newspaper Publication

Newspaper Publication

Copy of Newspaper Publication of Financial Results for the quarter ended June 30, 2026.

Company Update / Newspaper Publication View filing →
10 August 2026 · 21:01 IST

Monitoring Agency

Monitoring Agency Report

Monitoring Agency Report for the quarter ended June 30, 2026

Company Update / Monitoring Agency Report View filing →
10 August 2026 · 20:58 IST

General

Opening Of A New Corporate Office Of The Company

Opening of a new Corporate Office of the Company

Company Update / General View filing →
10 August 2026 · 20:56 IST

Registered Office

Change in Registered Office Address

Change in the Registered Office address of the Company, subject to the approval of shareholders and other Statutory Authorities.

Company Update / Change in Registered Office Address View filing →
10 August 2026 · 20:52 IST

Subsidiary Incorporation

Acquisition

Investment in Wholly Owned Subsidiary.

Company Update / Acquisition View filing →
10 August 2026 · 20:50 IST

Change in Directorate

Change in Directorate

Re-appointment of Managing Director, Independent Director and Continuation of Directorship of Non- Executive Director.

Company Update / Change in Directorate View filing →
10 August 2026 · 20:29 IST

Results

For Quarter Ended June 30, 2026.

Audited Standalone and Consolidated Financial Results for quarter ended June 30, 2026.

Result / Financial Results View filing →
10 August 2026 · 20:24 IST

Board Outcome

Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter Ended June 30, 2026.

Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.

Board Meeting / Outcome of Board Meeting View filing →
5 August 2026 · 14:55 IST

Board Meeting

Board Meeting Intimation for Approval Of Financial Results For Quarter Ended June 30, 2026

Valiant Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve financial results for ....

Board Meeting / Board Meeting View filing →

RSS feed for Valiant Laboratories Ltd · the 50 most recent filings

Price
Market cap
Sector
Index
PE
Latest quarter revenue
Net profit
Filings in the window